PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Cabozantinib S-malate

Drugs in development · updated 30 October 2026

Cabozantinib S-malate: clinical trials and development status

Other names and codes: Cabometyx, Cometriq

FDA verified identityApproved in the US (FDA)

As of 30 October 2026 Cabozantinib S-malate is in 23 active clinical trials (recruiting or ongoing, phases I–III) for 49 diseases. The most advanced phase is III.

23Active trials
IIIMost advanced phase
49Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Cabozantinib S-malate and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 49 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Bladder neoplasmIII3NCT05092958
Urethral neoplasmIII3NCT05092958
Neuroendocrine tumorIII2NCT03375320
Ureteral neoplasmIII2NCT05092958
Islet cell adenomaIII1NCT03375320
Non-functioning pancreatic endocrine tumorIII1NCT03375320
Renal cell carcinomaII8NCT03866382
Hepatocellular carcinomaII4NCT02867592
Prostatic NeoplasmsII3NCT03866382
Transitional cell carcinomaII3NCT03866382
Adrenocortical carcinomaII2NCT02867592
Endometrial neoplasmII2NCT03367741
Ewing sarcomaII2NCT02867592
Lung neoplasmII2NCT04310007
Medullary carcinomaII2NCT02867592
MelanomaII2NCT05136196
Non-small-cell lung carcinomaII2NCT01708954
OsteosarcomaII2NCT02867592
Penile neoplasmII2NCT03866382
Urogenital neoplasmII2NCT03866382
Adenocarcinoma, FollicularII1NCT03914300
Adrenal cortex neoplasmII1NCT06006013
Alveolar soft part sarcomaII1NCT02867592
CarcinomaII1NCT05136196
CarcinosarcomaII1NCT03367741
Central nervous system neoplasmII1NCT02867592
Clear-cell sarcomaII1NCT02867592
Head and neck squamous cell carcinomaII1NCT05136196
HepatoblastomaII1NCT02867592
Hypopharyngeal NeoplasmsII1NCT05136196

Everything on Cabozantinib S-malate

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch